(Q46452033)

22 December 2017

title

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis (English)

1 reference

22 December 2017

author

William Jeffery Sandborn

3

object named as

William J Sandborn

1 reference

22 December 2017

2

Gary R Lichtenstein

1 reference

22 December 2017

Stefan Schreiber

4

object named as

Stefan Schreiber

1 reference

22 December 2017

Michael A. Kamm

1

object named as

Michael A Kamm

1 reference

22 December 2017

author name string

Kirstin Lees

5

1 reference

22 December 2017

Karen Barrett

6

1 reference

22 December 2017

Raymond Joseph

7

1 reference

22 December 2017

publication date

1 January 2009

1 reference

22 December 2017

Inflammatory Bowel Diseases

published in

1 reference

22 December 2017

volume

15

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

1-8

1 reference

22 December 2017

Guidelines for the management of inflammatory bowel disease in adults

cites work

1 reference

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

Systematic review: adherence issues in the treatment of ulcerative colitis

21 January 2018

1 reference

Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations.

21 January 2018

1 reference

Determinants of life satisfaction in inflammatory bowel disease.

21 January 2018

1 reference

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

21 January 2018

1 reference

Side effects of corticosteroid therapy

21 January 2018

1 reference

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

21 January 2018

1 reference

Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis

21 January 2018

1 reference

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.20580

1 reference

22 December 2017

1 reference

22 December 2017